Vireo Growth (VREOF) Other financing activities (2021 - 2025)

Vireo Growth (VREOF) posted Other financing activities of $15406.0 for Q2 2025, down 33.34% sequentially from $23110.0 in Q1 2025.

Vireo Growth (VREOF) Other financing activities (2021 - 2025) Analysis & Trends

Vireo Growth has reported Other financing activities for 3 years, with the latest figure at $15406.0 in Q2 2025.

Quarterly Other financing activities changed N/A year-over-year to $15406.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $38516.0 (down 65.04% YoY) and the FY2025 annual result came in at $38516.0, down 44.71% from the prior year.
Other financing activities retreated to $15406.0 in Q2 2025 per VREOF's latest filing, from $23110.0 in the prior quarter.
Over five years, Other financing activities peaked at $966156.0 in Q1 2021 and troughed at $15406.0 in Q2 2025.
A 3-year average of $185897.7 and a median of $57009.0 in 2021 frame the typical range for Other financing activities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-
2	Teva Pharmaceutical Industries	43.41 Bn	39.75 Bn	2.15 Bn
3	Zoetis	31.83 Bn	30.15 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.77 Bn	22.97 Bn	5.10 Bn
5	United Therapeutics	22.27 Bn	19.61 Bn	683.80 Mn
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn
7	Neurocrine Biosciences	15.65 Bn	15.26 Bn	935.80 Mn
8	Elanco Animal Health	11.93 Bn	11.40 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-
10	Vireo Growth	491.44 Mn	349.14 Mn	95.30 Mn

Download Data